$35M Bristol Myers Squibb Milestone Boosts Janux Therapeutics Q1 Revenue Despite Widening Net Loss
summarizeSummary
Janux Therapeutics reported its first-quarter 2026 financial results, showing a widening net loss to $24.36 million, primarily driven by increased research and development (R&D) and general and administrative (G&A) expenses. However, the company secured a significant $35 million milestone payment from Bristol Myers Squibb, which contributed to collaboration revenue. Janux also provided pipeline updates, including the discontinuation of JANX008 development to reallocate resources and plans for future clinical data announcements for JANX007 and JANX011, as well as the initiation of JANX013. This milestone payment is a material positive for the company, offsetting the expected increase in R&D spending typical for a clinical-stage biopharma. Traders will be watching for the upcoming clinical data readouts in H2 2026 and H1 2027 as key catalysts.
At the time of this announcement, JANX was trading at $14.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $884.5M. The 52-week trading range was $12.12 to $35.34. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.